Ochre Bio
Developing therapies for the biggest liver health challenges
Ochre Bio is a biotech company focused on eliminating the need for liver transplants by developing RNA-based therapies for chronic liver disease. The company uses a Human Discovery Platform that combines proprietary gene perturbation atlases, AI, and human validation models such as perfused livers to identify and validate novel drug targets. Ochre Bio partners with major pharma companies including GSK and Boehringer Ingelheim to advance its pipeline.
Ochre Bio integrates proprietary human liver datasets with AI and human validation models to make causal predictions about drug targets, then develops RNA therapies in-house to rapidly advance candidates through the pipeline.
pharmaceutical partners and investors in liver disease therapeutics
Background.
- Status
- launched
- Business model
- unknown
- Company
- Ochre Bio
Founders
- Quin Willssite
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.